Elite Wealth Management Inc. Sells 44 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Elite Wealth Management Inc. reduced its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 6.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 686 shares of the medical instruments supplier’s stock after selling 44 shares during the quarter. Elite Wealth Management Inc.’s holdings in West Pharmaceutical Services were worth $226,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Fidelis Capital Partners LLC bought a new stake in West Pharmaceutical Services in the first quarter worth $27,000. Crewe Advisors LLC grew its position in West Pharmaceutical Services by 322.7% during the 2nd quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 71 shares during the last quarter. Quarry LP increased its stake in West Pharmaceutical Services by 155.3% in the 4th quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock worth $34,000 after purchasing an additional 59 shares during the period. Hazlett Burt & Watson Inc. bought a new stake in West Pharmaceutical Services in the first quarter valued at approximately $40,000. Finally, Northwest Investment Counselors LLC purchased a new stake in shares of West Pharmaceutical Services during the first quarter valued at approximately $40,000. 93.90% of the stock is currently owned by institutional investors.

West Pharmaceutical Services Trading Up 0.6 %

NYSE:WST opened at $310.92 on Friday. The firm has a market capitalization of $22.65 billion, a P/E ratio of 41.02, a P/E/G ratio of 10.58 and a beta of 1.01. West Pharmaceutical Services, Inc. has a 52 week low of $265.00 and a 52 week high of $413.70. The company has a quick ratio of 1.68, a current ratio of 2.34 and a debt-to-equity ratio of 0.03. The company has a fifty day moving average of $304.11 and a 200 day moving average of $337.96.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.22). The business had revenue of $702.10 million during the quarter, compared to the consensus estimate of $729.36 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The firm’s revenue for the quarter was down 6.9% compared to the same quarter last year. During the same period in the previous year, the business earned $2.11 earnings per share. On average, research analysts predict that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current year.

Insider Activity

In other news, VP Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $300.00, for a total transaction of $308,700.00. Following the sale, the vice president now owns 1,478 shares of the company’s stock, valued at approximately $443,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.